Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
November 21, 2024 05:30 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310 for Oral Lichen Planus, Advancing to Next Dose Group
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
November 12, 2024 05:30 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Secures Extended Market Exclusivity with Issuance of U.S. Patent for Liposomal Delivery Platform
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
November 01, 2024 16:30 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
October 29, 2024 08:30 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
October 15, 2024 05:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform
Michael Chancellor
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
September 25, 2024 08:30 ET | PRISM MarketView
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
September 24, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
August 27, 2024 08:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
August 22, 2024 05:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference
August 21, 2024 05:00 ET | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference